FEDERAL COURT OF AUSTRALIA
Albany Molecular Research Inc v Alphapharm Pty Ltd [2011] FCA 120
Citation: Albany Molecular Research Inc v Alphapharm Pty Ltd [2011] FCA 120 Parties: ALBANY MOLECULAR RESEARCH INC v ALPHAPHARM PTY LTD (ACN 002 359 739)
ALBANY MOLECULAR RESEARCH, INC v ARROW PHARMACEUTICALS PTY LTD (ACN 003 144 170), SIGMA PHARMACEUTICALS LIMITED (ACN 088 417 403), SIGMA PHARMACEUTICALS (AUSTRALIA) PTY LTD (ACN 004 118 594), SIGMA COMPANY LIMITED (ACN 004 132 923) and AVENTIS PHARMACEUTICALS, INC
File numbers: VID 219 of 2007
VID 883 of 2007Judge: JESSUP J Date of judgment: 18 February 2011 Catchwords: INTELLECTUAL PROPERTY – Patents – Whether patent invalid for want of novelty – Whether want of novelty established by disclosure of specific compound in terms in prior art base – Whether prior art needs to provide, for a skilled person working in the relevant area, information as to the means by which compound could practically and effectively be prepared – Whether prior art disclosed effective means – Whether further experiments and further information required in order to prepare compound – Whether further experiments and further information more than ordinary methods of trial and error
INTELLECTUAL PROPERTY – Patents – Whether patent invalid for lack of inventive step – Whether a skilled person faced with the problem of preparing the relevant compound in substantial purity would have been led, as a matter of routine, to try that which was invented under the patent in suit
INTELLECTUAL PROPERTY – Patents – Whether patent invalid due to inadequate description of invention or lack of clarity – Whether the expression “substantially pure” sufficiently clear
INTELLECTUAL PROPERTY – Patents – Amendment to specification – Whether amendment affected priority date – Whether matter claimed post amendment fell within scope of claims before amendment
INTELLECTUAL PROPERTY – Patents – Whether patent a manner of manufacture – Whether patent disclosed a new invention – Whether patent merely claimed a substance with desired attributes
INTELLECTUAL PROPERTY – Patents – Whether patent invalid for lack of sufficient description – Whether patent gave the best method known to the inventor of performing the invention
INTELLECTUAL PROPERTY – Patents – Whether patent invalid for lack of fair basis in the claims
INTELLECTUAL PROPERTY – Patents – Whether patent invalid due to false suggestion – Whether false suggestion made to commissioner – Whether false suggestion materially contributed to commissioner’s decision to grant patent, or was a material, inducing factor which led to grant
Legislation: Patents Act 1990 (Cth) ss 7, 18, 40, 114, 138
Patents Regulations 1991 (Cth) reg 3.14Cases cited: Abbott GMBH and Co KG v Apotex Pty Ltd (2010) 87 IPR 561
Acme Bedstead Co Ltd v Newlands Brothers Ltd (1937) 58 CLR 689
Aktiebolaget Hassle v Alphapharm Pty Ltd (2002) 212 CLR 411
Apotex Pty Ltd v Sanofi-Aventis (2009) 82 IPR 416
Eli Lilly and Co v Pfizer Overseas Pharmaceuticals (2005) 218 ALR 408
Hill v Evans (1862) 1A IPR 1, 6
H Lundbeck A/S v Alphapharm Pty Ltd
Keep reading for free
Create a free CaseChat account to read Albany Molecular Research Inc v Alphapharm Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2011] FCA 120
- Decision Date
CaseChat Overview and Summary
The court examined whether the prior art disclosed the compounds and an effective means for their preparation. It was argued that the prior art, specifically Carr 129 and Carr 146, did disclose the compounds and methods to prepare them. Experts in organic chemistry testified that the methods described in the prior art were straightforward and practical for preparing the compounds. The court concluded that the prior art provided sufficient information for a skilled person to prepare the compounds without needing further experiments or information beyond ordinary trial and error methods.
The court found that the prior art effectively disclosed the means for preparing the compounds, thus rendering the patent invalid for lack of novelty. Additionally, the court determined that the prior art would have led a skilled person to the invention through routine experimentation, negating the requirement for an inventive step. The court also found that the patent’s description was insufficient and the claims were not fair, as they were based on false suggestions made to the patent commissioner. Consequently, the court ruled that the patent was invalid on multiple grounds. The parties were directed to submit memoranda on the appropriate orders and costs within a specified timetable.
Orders
Orders of the court
1. The parties file and serve memoranda setting out their submissions as to the orders which should be made to reflect the court’s reasons published this day, together with any submissions as to costs, in accordance with the following timetable:
(a) the respondent/cross-claimant within seven days;
(b) the applicant/cross-respondent within a further seven days;
(c) the respondent/cross-claimant in reply (if necessary), within a further seven days.
Note:
1. The parties file and serve memoranda setting out their submissions as to the orders which should be made to reflect the court’s reasons published this day, together with any submissions as to costs, in accordance with the following timetable:
(a) the respondents/cross-claimants within seven days;
(b) the applicant/cross-respondents within a further seven days;
(c) the respondents/cross-claimants in reply (if necessary), within a further seven days.
Note:
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Before leaving this area of controversy, I should say something about the claim in the patent in suit to “substantially pure” compounds. Ultimately, it was not submitted on behalf of AMR that the Carr patents did not disclose the relevant compounds as such. AMR’s point, rather, was that, if the skilled addressee set about to prepare any one of these compounds in accordance with the instructions in Carr 129, he or she would not obtain para‑substituted purity. But it was not submitted that, if the view I take of the law as expounded in Lundbeck and Apotex be the correct one, the patent in suit stood apart from Carr 129 only because of the claim to substantial purity. Thus the point raised particularly by the Sigma respondents that the invention in suit was on any view anticipated by Claim 2 in Carr 146, which claimed “substantially pure” compounds, does not arise. It would, however, have been a complete answer to any contention by AMR that the very compound claimed under the patent in suit had not, in terms, been disclosed in the prior art. THE RESPONDENTS’ ALTERNATIVE CASE ON NOVELTY: EFFECTIVE MEANS OF PREPARATION In the alternative, the respondents submitted that, if it were necessary (to establish want of novelty) that the prior art base disclosed not only the compounds claimed in the patent in suit but also an effective means for their preparation, Carr 129 and Carr 146 did so. What would be perceived and understood, and what could be practically applied (see Hill v Evans) are, of course, questions to be approached from the perspective of the skilled addressee. Conformably with this requirement, the parties called organic chemists of some standing in their profession to opine on these questions. AMR called Prof Christopher Easton, Distinguished Professor at the Research School of Chemistry, Institute of Advanced Studies, Australian National University; Alphapharm called Prof David Black, Professor of Organic Chemistry at the University of New South Wales, and Prof Bruce Wild, Emeritus Professor in the Research School of Chemistry at the Australian National University; and the Sigma Respondents called Dr Alan Robertson, Chief Executive Officer and Managing Director of Pharmaxis Ltd. Although both Carr 129 and the patent in suit disclose a series of compounds, the question of effective means of preparation was addressed by the parties with reference to one only of them, 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1- hydroxybutyl]-α,α-dimethylbenzeneacetic acid, that is, fexofenadine. The parties’ cases were based on the implicit assumption that the means of preparation of this compound disclosed in Carr 129 might stand, in effect, as a proxy for the like means so disclosed with respect to the other compounds. I shall proceed by reference to that assumption. According to Carr 129, fexofenadine could be synthesised by the sequential combination of the methods described in Examples 5(A), 5(B), 2 and 3 therein, the product of each of which provided the starting material for the next. Part (A) of Example 5 is as follows:To 700 ml of carbon disulfide containing 36.5 g (0.254 mole) of 4-chlorobutyryl chloride is added 74.5 g (0.56 mole) of aluminum chloride with stirring at -10° C. Stirring is continued for about 15 minutes at about 25° C. then the mixture is recooled to 5° C. and 48.4 g (0.294 mole) of ethyl α,α-dimethylphenylacetate in 100 ml of carbon disulfide is added. The reaction mixture is stirred on an ice bath for 3½ hours then stirred to 15½ hours at 25° C. then poured into HCl-ice water and extracted with chloroform. The extract is washed with dilute sodium carbonate solution, water and saturated sodium chloride solution, dried over magnesium sulfate, and evaporated giving as a solid ethyl 4-(4-chloro-l-oxobutyl)-α,α-dimethylphenylacetate. Prof Wild described this as involving “a typical Friedel-Crafts acylation using aluminium chloride in carbon disulfide solvent”. He identified the reaction scheme as follows:All of the experts who expressed a view on the subject gave effectively the same evidence as Prof Wild, namely, that, when they first looked at example 5(A), they anticipated a relatively uncomplicated Friedel-Crafts acylation.